Compass Therapeutics (CMPX) Amortizatization of Intangibles (2021 - 2026)
Compass Therapeutics recorded quarterly Amortizatization of Intangibles of $353000.0 in Q1 2026, little changed quarter-over-quarter from $353000.0 in Q4 2025, and up 57.59% year-over-year from $224000.0 in Q1 2025.
Compass Therapeutics' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $353000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 57.59% year-over-year to $353000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 22.8% YoY), while the FY2025 annual figure was $1.2 million, up 2.75% from the prior year.
- Amortizatization of Intangibles came in at $353000.0 for Q1 2026 at Compass Therapeutics, roughly flat from $353000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $353000.0 in Q4 2025 to a low of $219000.0 in Q4 2024.
- A 5-year average of $295647.1 and a median of $295000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles retreated 28.66% in 2024 and jumped 61.19% in 2025, its largest moves.
- Compass Therapeutics' Amortizatization of Intangibles stood at $289000.0 in 2022, then advanced by 6.23% to $307000.0 in 2023, then declined by 28.66% to $219000.0 in 2024, then surged by 61.19% to $353000.0 in 2025, then changed by 0.0% to $353000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $353000.0, $353000.0, and $352000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 353,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 295,000.00 |
| Mar 31, 2023 | 287,000.00 |
| Mar 31, 2023 | 287,000.00 |
| Dec 31, 2022 | 289,000.00 |
| Dec 31, 2022 | 289,000.00 |
| Sep 30, 2022 | 285,000.00 |
| Sep 30, 2022 | 285,000.00 |
| Jun 30, 2022 | 278,000.00 |
| Jun 30, 2022 | 278,000.00 |
| Mar 31, 2022 | 270,000.00 |
| Mar 31, 2022 | 270,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Sep 30, 2021 | 268,000.00 |
| Sep 30, 2021 | 268,000.00 |
| Jun 20, 2021 | 262,000.00 |
| Jun 20, 2021 | 262,000.00 |
| Mar 31, 2021 | 256,000.00 |
| Mar 31, 2021 | 256,000.00 |